DRUG APPROVALS

October 16, 2019

Review of Selected NMEs 2019

Spotlighted are new molecular entities targeting solid tumors in patients with an NTRK gene fusion; acute lymphocytic leukemia; relapsed or refractory acute myeloid leukemia with FLT3 mutations; and locally advanced or multistatic breast cancer with a susceptible genetic alteration.

October 16, 2019

New Drug Review 2019

October 16, 2018

Review of Selected NMEs 2018

October 16, 2018

New Drug Review 2018

October 13, 2017

New Drug Review 2017

October 13, 2017

Review of Selected NMEs 2017

October 14, 2016

Review of Selected NMEs 2016

October 14, 2016

New Drug Review 2016

October 16, 2015

New Drug Review 2015

October 16, 2015

Review of Selected NMEs 2015

October 16, 2014

New Drug Review 2014

October 16, 2014

Review of Selected NMEs 2014